GlassScriptPhysician profile
Holly K Griffith
NPI 1750639209
$6,970.65
in general payments reported to CMS, 2019-2025
20 companies · $1,066 in 2025
The $1,066 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $606 · 2022: $1,142 · 2023: $1,883 · 2024: $2,274 · 2025: $1,066.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,205 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,205.24 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,173.33 | 2021-2024 | Xarelto |
| Heartflow, INC. | $977.89 | 2022-2025 | Ffrct |
| Novartis Pharmaceuticals Corporation | $764.33 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $646.03 | 2022-2025 | Jardiance |
| Amgen INC. | $614.80 | 2021-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $540.05 | 2023-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $465.40 | 2021-2025 | Lifevest |
| Pfizer INC. | $397.69 | 2022-2025 | |
| Boston Scientific Corporation | $349.20 | 2022-2025 | Watchman Flx, Watchman Access System, General - Therapies |
| Astrazeneca Pharmaceuticals LP | $295.06 | 2022-2025 | Farxiga |
| Abbott Laboratories | $173.01 | 2021-2023 | Aveir, Confirm Rx |
| Esperion Therapeutics, INC. | $153.65 | 2022-2025 | Nexletol |
| Biosense Webster, INC. | $144.20 | 2024 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $119.79 | 2022-2025 | Camzyos, Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $50.70 | 2024 | Arcalyst |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $35.84 | 2024 | Evkeeza |
| Bridgebio Pharma, INC. | $19.48 | 2025 | Attruby |
| Actelion Pharmaceuticals US, INC. | $17.65 | 2022 | |
| Cvrx, INC. | $16.71 | 2023 | Barostim Neo System |
| Terumo Medical Corporation | $15.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Griffith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.